JP2012522754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522754A5 JP2012522754A5 JP2012502694A JP2012502694A JP2012522754A5 JP 2012522754 A5 JP2012522754 A5 JP 2012522754A5 JP 2012502694 A JP2012502694 A JP 2012502694A JP 2012502694 A JP2012502694 A JP 2012502694A JP 2012522754 A5 JP2012522754 A5 JP 2012522754A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- disease
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09157303.0 | 2009-04-03 | ||
| EP09157303 | 2009-04-03 | ||
| PCT/EP2010/054418 WO2010115843A2 (en) | 2009-04-03 | 2010-04-01 | Pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015129383A Division JP2015214559A (ja) | 2009-04-03 | 2015-06-29 | 薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522754A JP2012522754A (ja) | 2012-09-27 |
| JP2012522754A5 true JP2012522754A5 (cg-RX-API-DMAC7.html) | 2013-05-09 |
| JP5810076B2 JP5810076B2 (ja) | 2015-11-11 |
Family
ID=42269736
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502694A Active JP5810076B2 (ja) | 2009-04-03 | 2010-04-01 | 薬学的組成物 |
| JP2015129383A Withdrawn JP2015214559A (ja) | 2009-04-03 | 2015-06-29 | 薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015129383A Withdrawn JP2015214559A (ja) | 2009-04-03 | 2015-06-29 | 薬学的組成物 |
Country Status (28)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US9605054B2 (en) * | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| DK2408807T3 (da) * | 2009-03-18 | 2021-08-09 | Ac Immune Sa | Fremgangsmåde til terapeutisk anvendelse |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| JP5917394B2 (ja) | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | 病理学的タウタンパク質の免疫学的標的化方法 |
| US9289488B2 (en) | 2010-08-12 | 2016-03-22 | Ac Immune Sa | Vaccine engineering |
| US9304138B2 (en) * | 2010-10-07 | 2016-04-05 | Katholieke Universiteit Leuven | Pharmaceutical composition |
| AU2013205313B2 (en) * | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
| CA2813833C (en) | 2010-10-26 | 2020-09-22 | Ac Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| KR20210099167A (ko) | 2011-09-19 | 2021-08-11 | 악손 뉴로사이언스 에스이 | 알쯔하이머병의 타우 매개된 병리학의 단백질 기재 요법 및 진단 |
| EP3135689B1 (en) * | 2011-10-07 | 2018-12-19 | AC Immune S.A. | Phosphospecific antibodies recognising tau |
| KR102132041B1 (ko) | 2012-04-05 | 2020-07-09 | 에이씨 이뮨 에스.에이. | 인간화된 타우 항체 |
| RU2657438C2 (ru) * | 2012-05-31 | 2018-06-13 | Осака Сити Юниверсити | Терапевтическое средство или профилактическое средство против деменции |
| KR20200013072A (ko) | 2012-07-03 | 2020-02-05 | 워싱턴 유니버시티 | Tau에 대한 항체 |
| AU2013302540B2 (en) * | 2012-08-16 | 2018-02-15 | Ipierian, Inc. | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| KR102233349B1 (ko) * | 2013-03-15 | 2021-03-31 | 에이씨 이뮨 에스.에이. | 항-타우(tau) 항체 및 사용 방법 |
| SG11201605044RA (en) | 2013-12-20 | 2016-07-28 | Hoffmann La Roche | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| EP3166688B1 (en) | 2014-07-08 | 2024-08-21 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| CA3258972A1 (en) | 2015-06-05 | 2025-04-17 | Ac Immune Sa | TAU ANTIBODIES AND METHODS OF USING THEM |
| WO2016207245A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| CN107849105B (zh) | 2015-07-06 | 2021-09-17 | Ucb生物制药有限责任公司 | Tau结合抗体 |
| EP3334453A4 (en) | 2015-08-13 | 2019-02-06 | New York University | ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| KR102674612B1 (ko) | 2016-12-01 | 2024-06-14 | 상가모 테라퓨틱스, 인코포레이티드 | Tau 조절제 및 그것의 전달을 위한 방법 및 조성물 |
| JP2020511937A (ja) | 2016-12-07 | 2020-04-23 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| WO2018106781A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| TWI853617B (zh) | 2017-10-16 | 2024-08-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| EP3700556A2 (en) | 2017-10-25 | 2020-09-02 | Janssen Pharmaceuticals, Inc. | Compositions of phosphorylated tau peptides and uses thereof |
| JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
| WO2020072677A1 (en) | 2018-10-02 | 2020-04-09 | Sangamo Therapeutics, Inc. | Methods and compositions for modulation of tau proteins |
| EP3877399A4 (en) | 2018-11-06 | 2022-10-19 | Alsatech, Inc. | CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES |
| BR112021014794A2 (pt) * | 2019-02-08 | 2021-10-05 | Ac Immune S.A. | Método de administração segura de vacina de peptídeo de tau fosforilada |
| US11591377B2 (en) | 2019-04-24 | 2023-02-28 | Janssen Pharmaceuticals, Inc. | Heterologous administration of tau vaccines |
| CN116723856A (zh) | 2020-06-25 | 2023-09-08 | 默沙东有限责任公司 | 靶向丝氨酸413处磷酸化的tau的高亲和力抗体 |
| US20240101654A1 (en) * | 2020-12-29 | 2024-03-28 | Neurimmune Ag | Human anti-tau antibodies |
| CA3243636A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | CONJUGATED COMPRISING AT LEAST ONE β-GLUCANE OR ONE MANNANA |
| KR102856378B1 (ko) * | 2022-09-30 | 2025-09-08 | 주식회사 젬백스앤카엘 | 4r 타우병증의 치료 또는 예방용 펩티드 |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| US7408027B1 (en) * | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| WO1994013795A1 (en) | 1992-12-14 | 1994-06-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
| AU5508798A (en) * | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| EA003739B1 (ru) * | 1997-12-03 | 2003-08-28 | Байоджен, Инк. | Гидрофобно-модифицированные белки, способы их получения и их применение |
| WO2002004949A2 (en) | 2000-07-11 | 2002-01-17 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
| EP1581203A1 (en) | 2002-12-24 | 2005-10-05 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| WO2007068105A1 (en) * | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| ES2407429T3 (es) * | 2005-12-12 | 2013-06-12 | Ac Immune S.A. | Vacuna terapéurica |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| JPWO2009051220A1 (ja) | 2007-10-19 | 2011-03-03 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| DK2408807T3 (da) * | 2009-03-18 | 2021-08-09 | Ac Immune Sa | Fremgangsmåde til terapeutisk anvendelse |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| JP5917394B2 (ja) | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | 病理学的タウタンパク質の免疫学的標的化方法 |
| AU2010277254B2 (en) | 2009-07-30 | 2015-05-07 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
-
2010
- 2010-01-04 UA UAA201112528A patent/UA107571C2/ru unknown
- 2010-04-01 BR BRPI1015088-9A patent/BRPI1015088B1/pt active IP Right Grant
- 2010-04-01 EP EP16179161.1A patent/EP3097925B1/en active Active
- 2010-04-01 NZ NZ595856A patent/NZ595856A/en unknown
- 2010-04-01 PT PT107131724T patent/PT2413957T/pt unknown
- 2010-04-01 CN CN201510822296.XA patent/CN105524160B/zh active Active
- 2010-04-01 MY MYPI2011004748A patent/MY171300A/en unknown
- 2010-04-01 KR KR1020157007957A patent/KR20150041203A/ko not_active Ceased
- 2010-04-01 CA CA2757345A patent/CA2757345C/en active Active
- 2010-04-01 JP JP2012502694A patent/JP5810076B2/ja active Active
- 2010-04-01 HU HUE16179161A patent/HUE044981T2/hu unknown
- 2010-04-01 CN CN201080024398.2A patent/CN102946899B/zh active Active
- 2010-04-01 EP EP10713172.4A patent/EP2413957B1/en active Active
- 2010-04-01 SG SG2011071909A patent/SG175037A1/en unknown
- 2010-04-01 DK DK16179161.1T patent/DK3097925T3/da active
- 2010-04-01 SI SI201031931T patent/SI3097925T1/sl unknown
- 2010-04-01 PL PL10713172T patent/PL2413957T3/pl unknown
- 2010-04-01 MA MA34202A patent/MA34120B1/fr unknown
- 2010-04-01 PT PT16179161T patent/PT3097925T/pt unknown
- 2010-04-01 DK DK10713172.4T patent/DK2413957T3/en active
- 2010-04-01 RU RU2011144307/15A patent/RU2582916C2/ru active
- 2010-04-01 ES ES10713172.4T patent/ES2595371T3/es active Active
- 2010-04-01 ES ES16179161T patent/ES2738623T3/es active Active
- 2010-04-01 KR KR1020117026246A patent/KR101770436B1/ko active Active
- 2010-04-01 WO PCT/EP2010/054418 patent/WO2010115843A2/en not_active Ceased
- 2010-04-01 AU AU2010233856A patent/AU2010233856B2/en active Active
- 2010-04-01 US US13/262,793 patent/US8647631B2/en active Active
- 2010-04-01 MX MX2011010353A patent/MX2011010353A/es active IP Right Grant
- 2010-04-01 PL PL16179161T patent/PL3097925T3/pl unknown
- 2010-04-01 HU HUE10713172A patent/HUE030428T2/en unknown
- 2010-04-01 SI SI201031297A patent/SI2413957T1/sl unknown
-
2011
- 2011-09-28 CR CR20110509A patent/CR20110509A/es unknown
- 2011-09-30 CO CO11129267A patent/CO6390113A2/es not_active Application Discontinuation
- 2011-10-02 IL IL215451A patent/IL215451A/en active IP Right Grant
- 2011-10-03 EC ECSP11011367 patent/ECSP11011367A/es unknown
- 2011-10-03 CL CL2011002457A patent/CL2011002457A1/es unknown
- 2011-10-24 ZA ZA2011/07776A patent/ZA201107776B/en unknown
-
2013
- 2013-09-16 US US14/028,415 patent/US20140255412A1/en not_active Abandoned
- 2013-10-08 CL CL2013002888A patent/CL2013002888A1/es unknown
-
2014
- 2014-12-19 US US14/577,325 patent/US20150259406A1/en not_active Abandoned
-
2015
- 2015-06-29 JP JP2015129383A patent/JP2015214559A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522754A5 (cg-RX-API-DMAC7.html) | ||
| JP7229980B2 (ja) | 病理学的タウタンパク質の免疫学的標的化方法 | |
| JP6174727B2 (ja) | 治療的特性を有するβ１〜４２特異的モノクローナル抗体 | |
| RU2011144307A (ru) | Фармацевтическая композиция | |
| JP5436414B2 (ja) | モノクローナル抗βアミロイド抗体 | |
| JP2011522842A (ja) | パーキンソン病に関連する症状の治療のための化合物 | |
| AU2012244075B2 (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| AU2015201763A1 (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1204579B (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1124532A (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1161141B (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1127486B (zh) | 治疗性疫苗 |